LifeMD (NASDAQ:LFMD) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of LifeMD (NASDAQ:LFMD) in a report released on Friday, Benzinga reports. Cantor Fitzgerald currently has a $15.00 target price on the stock.

Other equities analysts have also issued research reports about the company. B. Riley started coverage on LifeMD in a report on Friday, August 23rd. They set a buy rating and a $11.00 price objective on the stock. KeyCorp dropped their price target on LifeMD from $12.00 to $10.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $12.00.

LifeMD Price Performance

Shares of LFMD opened at $5.12 on Friday. The firm’s 50 day moving average price is $5.67 and its 200 day moving average price is $7.80. The company has a market cap of $213.80 million, a P/E ratio of -6.92 and a beta of 1.19. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. LifeMD has a fifty-two week low of $4.26 and a fifty-two week high of $12.88.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period in the prior year, the company earned ($0.23) EPS. On average, research analysts forecast that LifeMD will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeMD

Hedge funds have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of LifeMD during the 2nd quarter worth about $31,000. Los Angeles Capital Management LLC acquired a new position in shares of LifeMD in the 2nd quarter valued at $88,000. EntryPoint Capital LLC acquired a new position in shares of LifeMD in the 1st quarter valued at $89,000. The Manufacturers Life Insurance Company purchased a new stake in shares of LifeMD during the 2nd quarter valued at $93,000. Finally, XTX Topco Ltd purchased a new position in shares of LifeMD in the 2nd quarter worth $94,000. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.